A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Clinical trial NCT02000440 · COMPLETED

Trial details

NCT number: NCT02000440
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Glomerulosclerosis, Focal Segmental

Start date: 2014-07-01
Primary completion: 2016-02-29
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.